2027 Agenda: Day 3 - Wednesday 13 January - PT (Pacific Time, GMT-08:00)
The biopharma industry stands at a critical crossroads. While rapid scientific breakthroughs continue to revolutionize health care, the sector faces intense scrutiny. Rising geopolitical tensions, complex regulatory shifts, and public debates over drug pricing and equity have complicated the industry’s reputation. Instead of merely reacting to external pressures, how can industry leaders actively change the narrative? How do we communicate the true value of innovation and rebuild public trust?
China’s biopharma landscape continues to evolve as innovation, quality, and global dealmaking reshape its role in the industry. This session will explore the opportunities for licensing, partnerships, and cross-border transactions, and what global investors and biopharma companies need to know about engaging with China’s increasingly dynamic ecosystem.
AI is rapidly reshaping biopharma R&D, with the potential to accelerate clinical trials, improve decision-making, and streamline drug development. This session will explore how AI is moving from promise to application—and where it could create the greatest impact across the biopharma value chain.
The traditional closing discussion at Biotech Showcase where journalists are invited to discuss what was “heard around the square” and Biotech Showcase during the most important week in the biotech calendar.
Are new opportunities emerging for early-stage companies to access seed capital and build momentum? Leading investors will explore strategies for attracting early funding, emerging sources of capital, and the trends shaping venture investment in the next generation of biotech companies.